Date: 2014-04-15
Type of information: Licensing agreement
Compound: SynGEM® prefusion F vaccine candidate and Mimopath® platform
Company: Mucosis (The Netherlands) Changchun Bcht Biotechnology (China)
Therapeutic area: Infectious diseases
Type agreement:
Action mechanism: The Mimopath® technology is based on Lactococcus lactis. Mucosis has developed a robust proprietary technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be covered with antigens from viral, bacterial, parasitic or tumor origin. BLP-based vaccines are particularly suitable to administer into the nose or mouth, without the need for a needle. Such mucosal vaccines have been shown to raise protective immunity by activation of both the innate and the adaptive immune system. SynGEM®, Mucosis’s lead vaccine candidate which is currently completing preclinical studies, is being developed in cooperation with corporate, governmental and non-governmental partners across the globe. SynGEM® is designed to prevent infections with Respiratory Syncytial Virus (RSV). The unique RSV prefusion F protein in SynGEM® displays the most valuable epitopes thought to be important for optimal virus neutralization and is suitable for use in different formulations and administration routes to efficiently address various target groups.
Disease: prevention of Respiratory Syncytial Virus (RSV) infection
Details: * On April 15, 2014, Mucosis has announced that it has entered into a long-term collaboration and license agreement with China-based Changchun BCHT Biotechnology Co (BCHT). Under the agreement with BCHT, Mucosis will receive an equity investment along with customary payments including royalties in return for a license to its SynGEM® prefusion F vaccine candidate for prevention of RSV and the Mimopath® platform for other disease targets within the People’s Republic of China on an exclusive basis and non-exclusively in certain other Asian countries. Further details of the agreement were not disclosed. Changchun BCHT Biotechnology Co. was established in 2004 and is a 600-person biopharmaceutical enterprise engaging in research, development, production and marketing of vaccines, biologics and peptide drugs.
Financial terms:
Latest news:
